Tuesday, June 12, 2012

SGLT2 Inhibitors at ADA 2012 – Astellas' Ipragliflozin – The one to watch out for…


 
It seems Japanese companies are taking a lead in the SGLT2 space, as we are witnessing at ADA-2012.  Astellas Ipragliflozin and Mitsubishi Tanabe’s Canagliflozin have demonstrated a clinical profile that appears to be best in class.

It may be a bit premature to conclude on Ipragliflozin, as we are yet to see data in a larger population, but existing evidence is suggestive of best in class clinical profile, even better than canagliflozin.

In the ILLUMINATE study, Japanese patients inadequately controlled on metformin, were randomized to Ipragliflozin as add on to metformin and metformin alone arm in a 2:1 ratio. Patients on Ipragliflozin demonstrated a HbA1C reduction of 1.29% (is better than cana in the same population). Besides the rate of UTI events were lower in the Ipra arm compared to metformin alone, suggestive of best in class safety . Genital infections were higher in Ipra arm, but on a relative basis, it was still lower than observed with other SGLT2 pipeline drugs.